.jpg?format=webp&quality=80&width=3840)
The study has created patient-derived models for the rare malignancy Salivary Gland Adenoid Cystic Carcinoma (ACC). These models faithfully replicate the physical and genetic characteristics of the original tumors, opening new doors for drug studies. Notably, the study reveals the effectiveness of the bromodomain degrader, dBET6, in inhibiting ACC cells. This treatment significantly impacts the composition of ACC cell types, emphasizing the importance of targeting specific cell populations.
Like
Save
Share